Workflow
PCRX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In PCRX To Contact Him Directly To Discuss Their Options
PCRXPacira(PCRX) Prnewswire·2025-02-27 15:34

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pacira BioSciences, Inc. following the invalidation of its '495 patent, which has led to significant stock price declines and investor losses [2][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding 75,000inPacirabetweenAugust2,2023,andAugust8,2024,todiscusstheirlegaloptions[1].−ThefirmisremindinginvestorsoftheMarch14,2025,deadlinetoseektheroleofleadplaintiffinafederalsecuritiesclassactionagainstPacira[2].Group2:PatentInvalidationImpact−OnAugust9,2024,aNewJerseyDistrictCourtinvalidatedPacira′s′495patent,rulingthateVenusdidnotinfringeonthepatentduetoobviousnessandanticipation[4].−Theinvalidationannouncementsurprisedinvestors,leadingtoadramaticstockpricedeclinefrom75,000 in Pacira between August 2, 2023, and August 8, 2024, to discuss their legal options [1]. - The firm is reminding investors of the March 14, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Pacira [2]. Group 2: Patent Invalidation Impact - On August 9, 2024, a New Jersey District Court invalidated Pacira's '495 patent, ruling that eVenus did not infringe on the patent due to obviousness and anticipation [4]. - The invalidation announcement surprised investors, leading to a dramatic stock price decline from 22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, representing a decline of over 47% in a single day [5]. Group 3: Class Action Details - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6]. - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [6].